Back to top
more

Bellicum Pharmaceuticals, Inc. (BLCM)

(Delayed Data from NSDQ)

$3.15 USD

3.15
495,473

+0.13 (4.30%)

Updated May 3, 2019 04:00 PM ET

After-Market: $3.15 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Bellicum (BLCM) Down on Ending Development of CAR-T Candidates

by Zacks Equity Research

Following the decision to discontinue the development of pipeline candidates, Bellicum Pharmaceuticals (BLCM) is left with no candidate in clinical development. The stock is down 50% post the news.

Is Bellicum Pharmaceuticals (BLCM) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Bellicum Pharmaceuticals (BLCM) and Chemed (CHE) have performed compared to their sector so far this year.

Is Bellicum Pharmaceuticals (BLCM) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Bellicum Pharmaceuticals (BLCM) and Castle Biosciences, Inc. (CSTL) have performed compared to their sector so far this year.

Bellicum Pharmaceuticals (BLCM) Could Find Support Soon, Here's Why You Should Buy the Stock Now

by Zacks Equity Research

After losing some value lately, a hammer chart pattern has been formed for Bellicum Pharmaceuticals (BLCM), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Is Immunocore (IMCR) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Immunocore Holdings PLC Sponsored ADR (IMCR) and Bellicum Pharmaceuticals (BLCM) have performed compared to their sector so far this year.

Zacks.com featured highlights include: Bellicum Pharmaceuticals, Prometic Life Sciences, Vaccinex, Meridian Bioscience and 360 DigiTech

by Zacks Equity Research

Zacks.com featured highlights include: Bellicum Pharmaceuticals, Prometic Life Sciences, Vaccinex, Meridian Bioscience and 360 DigiTech

Sanghamitra Saha headshot

Bet on Rising P/E With These 5 Top-Ranked Stocks

by Sanghamitra Saha

Want to try some out-of-the-box approach? Tap five stocks with increasing P/E ratios.

Bellicum Pharmaceuticals (BLCM) Upgraded to Buy: Here's Why

by Zacks Equity Research

Bellicum Pharmaceuticals (BLCM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Karyopharm's (KPTI) Xpovio Gets FDA Nod for Second-Line Myeloma

by Zacks Equity Research

Karyopharm (KPTI) gets FDA approval for label expansion of its marketed drug, Xpovio, in combination with Takeda's Velcade and dexamethasone for treating multiple myeloma in second-line setting.

Sanghamitra Saha headshot

Bet on Rising P/E Investing With These Top 5 Stocks

by Sanghamitra Saha

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.

JAZZ's Zepzelca Combo SCLC Study Fails, Drug Still Promising

by Zacks Equity Research

JAZZ announces the failure of a combination regimen of SCLC drug, Zepzelca, to meet primary endpoint in a late-stage study. However, overall study data seems promising for the drug. Stock up.

Cronos Group (CRON) Catches Eye: Stock Jumps 9.3%

by Zacks Equity Research

Cronos Group (CRON) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

Bellicum Pharmaceuticals (BLCM) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

Bellicum Pharmaceuticals (BLCM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Sanghamitra Saha headshot

Rising P/E: An Ignored Trick to Pick 5 Winning Stocks

by Sanghamitra Saha

Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.

Pacira's (PCRX) Q2 Earnings Miss Estimates, Revenues In Line

by Zacks Equity Research

Pacira (PCRX) misses on earnings for the second quarter of 2020 while its revenues meet the mark.

Translate Bio Up on Vaccine Agreement Expansion With Sanofi

by Zacks Equity Research

Translate Bio (TBIO) and Sanofi expand their tie-up to develop mRNA vaccines for infectious diseases. The deal boosts the company's cash resources significantly along with potential future revenues.

Jazz's Aggressive Lung Cancer Drug Zepzelca Gets FDA Approval

by Zacks Equity Research

FDA's accelerated approval to Jazz's (JAZZ) Zepzelca as a monotherapy for metastatic small cell lung cancer patients set to boost the company's oncology portfolio.

Top Ranked Momentum Stocks to Buy for June 1st

by Zacks Equity Research

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, June 1st

All You Need to Know About Bellicum Pharmaceuticals (BLCM) Rating Upgrade to Strong Buy

by Zacks Equity Research

Bellicum Pharmaceuticals (BLCM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Bellicum Pharmaceuticals (BLCM) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

by Zacks Equity Research

Bellicum Pharmaceuticals (BLCM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Bellicum Pharmaceuticals (BLCM) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Bellicum Pharmaceuticals (BLCM) delivered earnings and revenue surprises of -1.75% and -65.67%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Bellicum Pharmaceuticals (BLCM) Q3 Earnings Expected to Decline

by Zacks Equity Research

Bellicum Pharmaceuticals (BLCM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Top Ranked Momentum Stocks to Buy for September 23rd

by Zacks Equity Research

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, September 23rd

Bellicum Pharmaceuticals (BLCM) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Bellicum Pharmaceuticals (BLCM) delivered earnings and revenue surprises of -7.41% and 497.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Bellicum Pharmaceuticals (BLCM) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

by Zacks Equity Research

Bellicum Pharmaceuticals (BLCM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.